

OPEN CALL



UEG-FTC
member
2014-2017



President Rolf GRAF
 Department of Surgery, Div. of
 Visceral & Transplant Surgery
 University Hospital
 Rämistrasse 100
 8091 Zurich
 Switzerland
 Tel: +41-44-2552071
 Fax: +41-44-2554449

Secretary Peter HEGYI
 First Department of Medicine
 Faculty of Medicine
 University of Szeged
 8-10 Koranyi fasor
 H-6720, Szeged
 Hungary
 Tel: +36-62-545200
 Fax: +36-62-545185

Treasurer Rolf GRAF
 Department of Surgery, Div. of
 Visceral & Transplant Surgery
 University Hospital
 Rämistrasse 100
 8091 Zurich
 Switzerland
 Tel: +41-44-2552071
 Fax: +41-44-2554449

APPLICATION FORM

**for European Pancreatic Club (EPC) representative
 in the Future Trends Committee (FTC) of the United European Gastroenterology
 (UEG)**

1	Personal data	<p>Name: Ákos Pap Username (www.e-p-c.org): Country: Hungary National Society: Hungarian Society of Gastroenterology</p>
2	Membership	<p>List of years when the applicant was member of EPC: Since 1992- continuously</p> <p>List of years when the applicant attended the annual EPC meeting: Since 1979 (Copenhagen) almost every years</p> <p>List of years when the applicant submitted (as first or last author) an abstract(s) for the annual EPC meeting: 1979, 1980, 1982, 1983, 1984, 1985, 1986, 1987, 1988, 1989, 1990, 1991, 1992, 1994, 1995, 1996, 1997, 1999, 2001, 2002, 2003, 2004, 2005, 2008, 2010, 2011, 2012.</p>
3	Publications	<p>List of the best 5 original/review papers in international journals: Pap Á., Varró V.: Intranasal cholecystokinin octapeptide in chronic pancreatitis. Lancet. 1977; 2(8032): 294, (Letter to the Editor).</p> <p>Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW. Related: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358 (9293): 1576-1585</p> <p>Neoptolemos J.P., Stocken D.D., Friess Helmut, Claudio bassi, janet A. Dunn, Helen Hickey, Hans Beger, Laureano fernandez-Cruz, Paolo Pederzoli, Akos Pap, David Spooner, David J. Kerr, Markus W. Büchler.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl j Med, 2004; 350 (12): 1200-1210</p> <p>Schwab R, Pinter F, Moldvay J, Papay J, Strausz J, Kopper L, Keri Gy, Pap A, Petak I., Oreskovich K., Mangel L.: Case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. J Clin Oncology, 2005; 23 (30): 7736-7738</p> <p>Gyökeres T., Schwab R., Burai M., Pap A.: Intraluminal duodenal duplication-endoscopic therapy is recommended even without previous pancreatitis and jaundice. Gastrointest Endosc. 2008; 68 (6): 1244-1245.</p>

4	Previous positions at EPC or UEG	Abstract selection committee (1994-1998) EPC Council (1998-2002) Regional representative of UEGF (2010-2013)

The applicant confirms that she/he

- has read the Open call for UEG Future Trends Committee Member position and fully accept its content
- has adequate time resources for volunteer work
- has good command of spoken and written English
- will attend all UEG FTC meetings to represent EPC. Please note that the UEG FTC usually meets twice a year
- will send a report (maximum of 3 pages) to the EPC secretary within a month after UEG FTC meetings which report will be published online on the webpage of EPC
- will be available for the EPC council meeting during the annual EPC meeting in order to discuss the UEG FTC matters during the period in which he/she represents EPC at the UEG FTC
- declare that she/he fully accepts the UEG Committee Guidelines available on the webpage of UEG and EPC

Name Ákos Pap MD.. ScD

Date 06.05. 2013.

Mission statement

As a clinician, operative endoscopist and pancreatologist interested in experimental and clinical pancreatology as well, I was deeply involved in the story of Revision of Atlanta Classification working first in Omaha with D. Magee, then at Mayo Clinic with E.P. DiMagno and M. Sarr. The success of treatment in severe acute pancreatitis began with getting insight into the interdigestive motility coupled with cyclic secretory activity of the pancreas, the ileal brake and other physiological mechanisms putting the pancreas into rest, meantime increasing peristalsis and intestinal circulation preventing bacterial translocation during jejunal feeding. Later on development of interventional radiology then endoscopic cystogastrostomy allowed delay of surgery even in septic patients until 5-6 weeks decreasing mortality of severe acute pancreatitis from 30-40 % to 6-7 %. However, limited knowledge about interdigestive motility resulted in again 16 % mortality with the aid of innocent probiotics injected them as bolus into the jejunum instead of perfusion in the Propatria study. Translational research should be the first step also in the case of such a devastating disease as pancreatic cancer. We learned from the studies of colorectal cancer (Cristal, Celim) just by analysing successful cases of the trials that K-ras (BRAF etc) mutations can prevent efficacy of tyrosine kinase inhibitors. Similar secondary analysis should be applied in the rare long-term survivals of pancreatic cancer.

However, early diagnosis of the disease should be attempted. We know (Nature 2010), that we have 17 years to diagnose early pancreatic cancer. We would need a combined screening method with markers (miRNA, CRP, CA19-9 etc) and imaging techniques, secondary prevention in high risk families by stopping smoking and alcohol consumption with dietetic interventions (green tea, resveratrol, soya products etc). Normal life expectancy in the French PRSS1 mutation follow-up study demonstrated that prevention of risk factors can diminish mortality even in this inherited situation.

However, interventional trials should be well controlled already in precancerous states as the chronic pancreatitis. Pancreatic diabetes treated with metformin and dietetic interventions without incretins and other insulin mobilisers, the abdominal obesity, alcoholism and mainly the smoking need long lasting behavioural therapy. Financing of these long studies might be difficult. To convince patients with heavy alcoholism and smoking seems to be extremely difficult, too. That could be the cause of the unexpected failure of the Dutch study demonstrating less pain after surgery than after operative endoscopy. Temporary stenting of the pancreatic duct can be effective only in cases stopped smoking and alcohol consumption, while longitudinal pancreatico-jejunoscopy keeps stenosis open even in smokers for a long time. Naturally, the best surgery should be compared with the best operative endoscopy. Quality control seems to be highly important in clinical studies, too. That happened in the Netherlands, too, when severe acute pancreatitis was treated by selected endoscopic centers, working with significantly less complications and diminished SIRS markers compared to surgery. The future is speaking in favour of a well balanced combination of good basic pancreatologists and clinicians working in one team or at least in close cooperation planning and executing research and clinical studies together.

In Hungary, the team has just got together some months ago, the results are waiting for the future and more and more hard workers. Good luck!

I would like to be one of the promoters of this movement not only at the national level but also in the EPC, moreover in the FTC using my long experience as research-fellow, clinician and previous officer of both EPC and UEG.

CURRICULUM VITAE

Name: Akos Pap
Position: Head of Department
National Institute of Oncology, Department of Gastroenterology/Endoscopy

University: High school in Hódmezővásárhely 1960-1964
Szeged Medical University 1964-1970
MD. with award "sub auspiciis rei publicae popularis" 1972
Specialist of Internal Medicine 1975
Gastroenterology 1980

Academic degree:

Hungarian Academy of Sciences:
PhD 1981 ScD. 1991

Languages

English
French

Employment and positions

1970-1989 Szeged Medical University Associated professor of medicine (last position)
1989-1998 2nd Dept. Med. Head of Dept. St. Imre Hospital, Budapest,
1996 Professor of Medicine
1998-2007 Head of Dept. Gastroenterology, MÁV Hospital, Budapest
2007-2013 Budaörs Medical Center – Head of Gastroenterology
2007- National Institute of Oncology – Head of Dept. Invasive Gastroenterology/Endoscopy,
Budapest

Professional activity

Physician, Gastroenterologist, Pancreatologist.

Research interest:

Gastroenterology, pancreatology, endoscopy

Fellowships abroad

1978-1979 Marseille, Inserm
1982-Creighton Univ., Omaha, Nebraska
1989-1990 Mayo Clinic, Rochester, MN

Honours and award

Boltz Award Mayo Clinic, Rochester, MN.

Memberships and committees in professional societies

Member of International Association of Pancreatology (1984-) and
editorial board of Int. J. Pancreatol. (1986-)

American Pancreatic Association (1987-)
Mayo Alumni Association (1989-),
Phoenix Alliance Inc. (1992-),
European Pancreatic Club (1992-),
General secretary of Pancreatic Section of Hungarian Gastroenterological Society (1992-1996),
American Gastroenterological Association (1993-),
Governing board of International Association of Pancreatology (1994-2002),
Abstract Selection Committee of European Pancreatic Club (1994-1998),
International Gastro-Surgical Club (1994-),
Hungarian Artificial Nutrition Society (1994-), Council (1995-2003)
President of Pancreatic Section of Hungarian Gastroenterological Society (1996-)
Treasurer of Hungarian Gastroenterological Society (1996-2000)
EPC Council (1998-2002)
Regional Editor of the Journal for Europe for IJDM (2001-)
PancreasWeb Advisor Boarding (2002-)
President of Oncology Section of Hungarian Gastroenterological Society (2002-);
President of Hungarian Society of Clinical Nutrition (2003-2006)
American Motility Society (2004-)
General Secretary of Hungarian Gastroenterological Society (2004-2006)
President elect of Hungarian Gastroenterological Society (2006-2008)
President of Hungarian Gastroenterological Society (2008-2010)
Past president of Hungarian Gastroenterological Society (2010-2012)
Regional representative of UEGF (2010-)

International collaborations (resulting publications)

Marseille Inserm U 46
Creighton Univ., Omaha, Nebraska
Mayo Clinic, Rochester

Most important subjects taught at university:

Pancreatology, Endoscopy, Artificial nutrition, Gastrointestinal oncology

Ákos Pap, M.D., Ph.D, Sc.D.

List of main publications

Pap Á., Lechene de la Porte P, Sarles H.:

Exogenous and endogenous stimulations during different phases of pancreatic secretion in conscious rats. *Pflügers Arch.* 1979; 383: 19-27.

Laugier R., Pap Á., Demol P., Charbit J.J., Sarles H.:

Pancreatic secretory response to cholecystokinin-pancreozymin and caerulein in the conscious rat. *Pflügers Arch.* 1980; 384: 83-92.

Pap Á., Berger Z., Varró V.:

Trophic effect of cholecystokinin-octapeptide in man. A new way in the treatment of chronic pancreatitis. *Digestion* 1981; 21: 163-168.

Pap Á., Flautner L., Tihanyi T., Papp J., Szécsényi A., Varró V.:

Pancreatic function after endoscopic and surgical occlusion of the pancreatic duct in patients with chronic pancreatitis. *Endoscopy* 1985; 17: 60-63.

Magee D.F., Naruse S., Pap Á.:

Comparison of the action of cholinomimetics and pentagastrin on gastric secretion in dogs. *Br. J. Pharmac.* 1985; 84: 347-355.

Pap Á., Sarles H.:

Effect of atropine on pancreatic secretion in conscious rats. *Digestion* 1986; 33: 17-25.

Bodoky Gy., Harsányi L., Pap Á., Tihanyi T., Flautner L.:

Effect of enteral nutrition on exocrine pancreatic function. *Am J. Surg.* 1991; 161: 144-148.

Pap A., Bradberry CW.:

Excitatory amino acid antagonists attenuate the effects of cocaine on extracellular dopamine in the nucleus accumbens. *J Pharmacol Exp Ther.* 1995; 274: 127-133.

Pozsár J., Berger Z., Simon K., Kovácsai A., Marosi E., Pap Á.:

Biphasic effect of prostaglandin E₁ on the severity of acute pancreatitis induced by a closed duodenal loop in rats. *Pancreas* 1996;2: 159-164

Pap Á., Topa L., Berger Z., Flautner L., Varró V.:

Pain relief and functional recovery after endoscopic intervention for chronic pancreatitis. *Scan. J. Gastroent.* 1998; 33: 98-106.

Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, Kordecki H, Schmid V.:

Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). *Aliment Pharmacol Ther.* 1998; 12: 1055-1065.

Tejeda M., Gaal D., Schwab RE., Pap A., Kéri Gy.:

In vivo antitumor activity of TT-232 a novel somatostatin analog. *Anticancer Research* 1999; 19 (4B): 3265-3268

Bayerdorffer E, Lonovics J, Dite P, Dietsch U, Domjan L, Kisfalvi I, Megraud F, Pap A, Sipponen P, Burman C, Zeijlon L.:

Efficacy of two different dosage regimens of omeprazole, amoxicillin and metronidazole for the cure of helicobacter pylori infection. *Aliment Pharmacol Ther.* 1999; 13: 1639-1645.

Meineche-Schmidt V, Talley NJ, Pap A, Kordecki H, Schmid V, Ohlsson L, Wahlqvist P, Wiklund I, Bolling-Sternevald E.:

Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study. *Scand J Gastroenterol.* 1999; 34: 566-574.

Dull JS., Topa L., Balgha V., Pap A.:

Non-surgical treatment of biliary liver abscesses: efficacy of endoscopic drainage and local antibiotic lavage with nasobiliary catheter. *Gastrointest Endosc.* 2000; 51: 55-59.

Tejeda M., Gaal D., Schwab RE., Pap A., Szuts T., Keri Gy.:

Influence of various administration routes on the antitumor efficacy of TT-232, a novel somatostatin analog. *Anticancer Res.* 2000; 20 (2A): 1023-1027.

Schwab R., Szegedi Z., Tejeda M., Nemeth BB., Hamvas J., Szende B., Eberle AN., Pap A.:

Activation of trypsinogen in the course of apoptosis triggers necrosis in the arginine induced pancreatitis model, in vitro. *Cytometry* 2001; 46: 211-212.

Schwab RE., Froidevaux S., Paku S., Tejeda M., Szende B., Pap A., Beglinger C., Eberle AN., Kéri Gy.:

Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours. *Anticancer Research* 2001; 21 (1A):71-76

Gyökeres T., Topa L., Marton I., Pap Á.:

Endoscopic cystogastrostomy during pregnancy. *Gastrointest Endoscopy* 2001; 53: 516-518

Hamvas J, Schwab R, Pap A. Related Articles:

Jejunal feeding in chronic pancreatitis with severe necrosis. *JOP.* 2001; 2:112-116.

Pap Á., Gyökeres T.:

Hasnyálmirigy-pseudociszták endoszkópos megoldása. *Eur J of Gastroent Hepatol (magyar kiadás)* 2002; 2: 49-53.

Gyökeres T., Schwab R., Burai M., Bor K., Pap Á.:

Duodenal duplication cyst. *Endoscopy*, 2002; 34: 503-504

Lasztity N., Biro L., Nemeth E., Pap A., Antal M.:

Protein status in pancreatitis – transthyretin is a sensitive biomarker of malnutrition in acute and chronic pancreatitis. *Clin Chem Lab Med* 2002; 40: 1320-1324

Gyökeres T., Duhl J., Varsányi M., Schwab R., Burai M., Pap Á.:

Double guide wire placement for endoscopic pancreaticobiliary procedures. *Endoscopy* 2003; 35: 95-96

Gyökeres T., Burai M., Hamvas J., Varsányi M., Mácsai M., Köveskúti Á., Fekete C., Pap Á.:

Conservative vs. endoscopic closure of colocolic fistulas after percutaneous endoscopic gastrostomy complications. *Endoscopy* 2003; 35: 246-247

Gyökeres T., Schwab R., Pap A.:

Endoscopic cystenterostomy of nonbulging pancreas fluid collections without EUS: Do we really need a communication between the cyst and the duct? *Gastrointestinal Endosc (Letter to the Editor)* 2003; 6: 807-808

Verlaan M., Morsche R.H.M., Pap A., Laheij R.J.F., Jansen J.B.M.J., Peters W.H.M., Drenth J.P.H.:

Functional polymorphisms of UDP-glucuronosyltransferases 1A1, 1A6 and 1A8 are not involved in chronic pancreatitis. *Pharmacogenetics* 2004, 14: 351-357

Demeter P., Pap Á.:

The relationship between gastroesophageal reflux disease and obstructive sleep apnea. *J Gastroenterol* 2004; 39: 815-820

Pinter F., Schwab R., Petak I., Diofalvi K., Tihanyi B., Varga G., Paku S., Pap A., Kopper L., Keri G.:

Detection of signal transduction molecular targets in gastrointestinal tumours. *Tiss Antigens* 2004; 64: 389-390.

- Varkondi E., Juhasz H., Nagy K., Schwab R., Pap A., Kopper L., Keri G., Petak I.:
Preparation of human EGFR intracellular domain-GST fusion protein with recombinant technique. *Tiss Antigens* 2004; 64: 431-432.
- Sukopp M., Schwab R., Marinelli L., Biron E., Heller M., Varkondi E., Pap A., Novellino E., Keri G., Kessler H.:
Structure-activity relationship studies optimizing the antiproliferative activity of novel cyclic somatostatin analogues containing a restrained cyclic beta-amino acid. *J Med Chem* 2005; 48: 2916-2926.
- Várkondi E., Schafer E., Bökönyi G., Gyökeres T., Örfi L., Peták I., Pap Á., Szokolóczy O., Kéri Gy., Schwáb R.:
Comparison of ELISA-based tyrosinkinase assays for screening EGFR inhibitors. *J Recept Sig Transd.* 2005; 25: 45-56.
- Verlaan M., Harbers EGA., Pap A, Jansen JBMJ., Peters WHM., Drent JPH.:
Paraoxonase 1-192Q allele is a risk faktor for idiopathic chronic pancreatitis. *J Mol Diag* 2005; 9:9-15
- Lasztity N., Hamvas J., Biro L., Németh É., Marosvölgyi T., Decsi T., Pap Á., Antal M:
Effect of enterally administered n-3 polyunsaturated fatty acids in acute pancreatitis – a prospective controlled trial. *Clin Nutr* 2005; 24: 198-205.
- Szokolóczy O., Schwab R., Peták I., Örfi L., Pap Á., Eberle A.N., Szüts T., Kéri Gy.:
TT232, A novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases. *J Recept Sign Transd* 2005; 25 : 217 – 235
- Meier R., Ockenga J., Pertkiewicz M., Pap A., Milinic N., MacFie J., Loser C., Keim V.:
ESPEN guidelines on enteral nutrition: Pancreas. *Clin Nutr* 2006; 25: 275-284.
- Schwab R, Micsik T, Szokolóczy O, Schafer E, Tihanyi B, Tihanyi T, Kupcsulik P, Diófalvi K, Mersich T, Besznyak I Jr, Zarand A, Mihalik R, Sarkadi B, Kéri G, Pap A, Jakab F, Kopper L, Petak I.:
Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors. *Assay Drug Dev Technol.* 2007; 5:541-50.
- Schwab R, Micsik T, Szokolóczy O, Schafer E, Tihanyi B, Tihanyi T, Kupcsulik P, Diófalvi K, Mersich T, Besznyak I Jr, Zarand A, Mihalik R, Sarkadi B, Kéri G, Pap A, Jakab F, Kopper L, Petak I.:
Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors. *Assay Drug Dev Technol.* 2007; 5: 541-50.
- Lohr M., Haas S., Bechstein WO., Bodoky Gy., Jager D., Karrasch M., Mescheder A., Meyer I., Pap A., Folsch U.:
12-month survival data of a phase II trial: first line treatment of inoperable Pancreatic adenocarcinoma with cationic lipid complexed paclitaxel nanoparticles (endotag-1 (r) plus gemcitabine compared with gemcitabine monotherapy. *Ann Oncol (suppl)* 2008; 19: 2-3.
- Santhosh S., Witt H., Morsche te RHM., Némoda Z., Molnár T., Pap A., Jansen JB., Drenth JP.:
A loss of function polymorphism (G191R) of anionic trypsinogen (PRSS2) confers protection against chronic pancreatitis. *Pancreas* 2008; 36: 317-320.
- Czakó L., Gyökeres T., Topa L., Sahin P., Takács T., Vincze Á., Dubravcsik Zs., Szepes A., Pap Á., Földesi I., Terzin V., Tiszlavicz L., Wittmann T.:
Autoimmune Pancreatitis in Hungary: A Multicenter Nationside Study. *Pancreatology* 2011; 11:261-267.
- Psáder R, Sterczer A, Pápa K, Harnos A, Szilvási V, Pap A.
Effect of enteral feeding on gallbladder function in dogs.
Acta Vet Hung. 2012; 60: 211-22.